Cost-effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China.
Objective: To assess the cost-effectiveness of clopidogrel versus aspirin for high risk patients (pre-existing symptomatic atherosclerosis or multi-vascular territory involvement) with established peripheral arterial disease (PAD) for secondary prevention of atherothrombotic events in a Chinese setting.Methods: A Markov model with a lifetime horizon was developed from the perspective of the national healthcare system in China. The primary outputs are quality adjusted life years (QALYs), direct medical costs, and the incremental cost-effectiveness ratios (ICERs). Clinical efficacy data were obtained from the CAPRIE trial. Drug acquisition cost, other direct medical costs, and utilities were from pricing records and the literature. One-way sensitivity analysis and probabilistic sensitivity analysis (PSA) were conducted to test the robustness of the model on all parameters.Results: In patients with pre-existing atherosclerosis, 2 years of treatment with clopidogrel and aspirin would yield total QALYs of 8.776 and 8.576 at associated costs of ¥18,777 ($2,838) and ¥12,302 ($1,859), respectively, resulting in an ICER of ¥32,382 ($4,893) per QALY gained. In patients with PVD, secondary prevention with the same drugs would expect to lead to total QALYs of 8.836 and 8.632 at associated costs of ¥18,518 ($2,798) and ¥12,041 ($1,820), respectively, resulting in a corresponding ICER of ¥31,743 ($4,797) per QALY gained. The results were most sensitive to the discount rate for future outcomes and costs. The PSA indicated that the probability of clopidogrel being cost-effective was 100% at the willingness-to-pay threshold of 3-times GDP.Conclusions: Secondary prevention with clopidogrel is an attractive cost-effective option compared with aspirin for high risk patients with established PAD from the perspective of the national healthcare system in Chinese settings.
['Lin|Ziyi|Z|', 'Zhang|Lei|L|', 'Yang|Xiaoyan|X|', 'Liu|Li|L|', 'Xuan|Jianwei|J|']
D001241:Aspirin D000077144:Clopidogrel D003362:Cost-Benefit Analysis D005102:Health Expenditures D006801:Humans D008390:Markov Chains D017059:Models, Econometric D058729:Peripheral Arterial Disease D010975:Platelet Aggregation Inhibitors D019057:Quality-Adjusted Life Years D055502:Secondary Prevention D013927:Thrombosis
cost-effectiveness analysis Clopidogrel aspirin peripheral arterial disease I12 I15